The Personalis Mission
To transform the development of next-generation cancer therapies by providing more comprehensive molecular data about each patient’s tumor.

Elucidating Complex Biology for the Immuno-Oncology Era

Personalis, a leader in advanced genomics for cancer, is focused on providing the most extensive molecular view of a patient’s tumor and characterizing its interplay with the immune system. By partnering with some of the world’s largest and most innovative biopharmaceutical companies, Personalis aids in the development of safer, more effective precision cancer therapies and personalized medicines.
The success of the checkpoint blockade has demonstrated that when tumor-imposed brakes are taken off the immune system, the subsequent immune response can effectively and – in some cases – completely eliminate tumor masses and cure patients. However, only a small minority of cancer patients have so far benefitted from this cancer immunotherapy revolution. Effectively and routinely predicting response to immunotherapies — and developing new ones — requires a more comprehensive approach to tumor immunogenomics and biomarker discovery. This is why we’ve developed the ImmunoID NeXT Platform™.

ImmunoID NeXT™

The Universal Cancer Immunogenomics Platform

ImmunoID NeXT is the first platform to enable the comprehensive analysis of both a tumor and its microenvironment from a single sample. Providing genomic information relating to all ~20,000 genes, ImmunoID NeXT consolidates multiple oncology biomarker assays into one – maximizing the biological insights garnered from a single, precious sample. When samples are in limited supply, researchers must make the difficult decision around which biomarkers to analyze.
With ImmunoID NeXT, this problem is a thing of the past.

A Single Platform. A Single Sample. Multiple Biomarkers.

Predictive & Investigational
Biomarker Discovery

ImmunoID NeXT provides a multidimensional view of the tumor and the TME, empowering our partners to extract the most information from the least amount of sample.

Personalized Cancer
Therapeutic Development

ImmunoID NeXT is the premier platform for the identification of neoantigens at the preclinical, clinical trial, and post-approval stages of the drug development process.

Ready to streamline your precision oncology 
translational and clinical research programs?

Join Us!
  • AACR Tumor Immunology and Immunotherapy Conference USA, Boston, MA | November 17-20
  • NeoAG Summit USA, Boston, MA | November 21-22
  • ESMO Immuno-Oncology Congress, Geneva, Switzerland | December 11-14